1,249 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Purchased by AGF Management Ltd.

AGF Management Ltd. purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,249 shares of the company's stock, valued at approximately $516,000.

Several other hedge funds and other institutional investors also recently modified their holdings of IDXX. Inspire Advisors LLC grew its stake in IDEXX Laboratories by 15.2% during the fourth quarter. Inspire Advisors LLC now owns 1,241 shares of the company's stock valued at $513,000 after acquiring an additional 164 shares in the last quarter. King Luther Capital Management Corp grew its stake in IDEXX Laboratories by 3.7% during the fourth quarter. King Luther Capital Management Corp now owns 4,872 shares of the company's stock valued at $2,014,000 after acquiring an additional 175 shares in the last quarter. Citizens Financial Group Inc. RI raised its position in shares of IDEXX Laboratories by 7.2% during the 4th quarter. Citizens Financial Group Inc. RI now owns 914 shares of the company's stock valued at $378,000 after buying an additional 61 shares in the last quarter. Sage Mountain Advisors LLC raised its position in shares of IDEXX Laboratories by 9.9% during the 4th quarter. Sage Mountain Advisors LLC now owns 612 shares of the company's stock valued at $253,000 after buying an additional 55 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its position in shares of IDEXX Laboratories by 7.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 17,748 shares of the company's stock valued at $7,338,000 after buying an additional 1,286 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Remove Ads

Insider Activity

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company's stock.

IDEXX Laboratories Trading Up 0.6 %

Shares of IDXX traded up $2.63 during trading hours on Wednesday, reaching $422.15. 462,350 shares of the company traded hands, compared to its average volume of 548,739. The company's fifty day moving average price is $437.74 and its two-hundred day moving average price is $445.87. The company has a market capitalization of $34.33 billion, a price-to-earnings ratio of 39.56, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $548.88.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Morgan Stanley lowered their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Bank of America raised their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Leerink Partners started coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus price target of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.